BioStacksSleep — Clinical Research
Evidence from published RCTs, systematic reviews, and meta-analyses.
Last reviewed: 3 March 2026
Strong Clinical Evidence
Melatonin
HIGHTherapeutic dose: 0.5–5 mg/day (peaks at ~4 mg)
- Meta-analysis of 19 RCTs (1,683 subjects) found melatonin significantly reduced sleep onset latency (7 min), increased total sleep time (8 min), and improved overall sleep quality. Effects did not dissipate with continued use.
- 2024 dose-response meta-analysis of 26 RCTs found melatonin's sleep benefits peak at 4 mg/day. Administering 3 hours before bedtime (not 30 minutes) optimized efficacy.
- 2022 meta-analysis of 23 RCTs found significant improvement in PSQI scores (WMD: -1.24, p < 0.001).
- 2026 scoping review identified 57 systematic reviews comprising 227 meta-analyses — confirming melatonin as the most-studied sleep supplement.
- Important nuance: absolute effect sizes are modest. Melatonin is a circadian signal (zeitgeber), not a sedative — mega-dosing above 4-5 mg offers diminishing returns.
Magnesium
MODERATE-HIGHTherapeutic dose: 200–400 mg/day elemental magnesium
- 2021 meta-analysis of 3 RCTs (151 older adults) found magnesium reduced sleep onset latency by 17 minutes (p = 0.0006).
- 2025 large RCT (153 participants) of magnesium bisglycinate found a small but significant reduction in Insomnia Severity Index scores (d = 0.2), with most improvements within the first 14 days.
- Dual mechanism: GABA-A receptor agonist + NMDA receptor antagonist. Increases slow-wave sleep, reduces cortisol, and increases melatonin production.
- ~50% of US adults have inadequate magnesium intake. Benefits are much more pronounced in magnesium-deficient individuals.
- Form matters enormously: bisglycinate ~80% bioavailability vs oxide 4-10%. A '500 mg magnesium oxide' product delivers ~30-50 mg absorbable magnesium.
L-Theanine
MODERATE-HIGHTherapeutic dose: 200–400 mg/day
- 2025 meta-analysis of 18 RCTs (897 participants) found L-theanine significantly improved subjective sleep onset latency (SMD = 0.15), daytime dysfunction (SMD = 0.33), and overall sleep quality (SMD = 0.43).
- Crucially, objective sleep measures (actigraphy, PSG) did NOT improve — benefits were subjective only.
- 2025 separate systematic review confirmed improvements across doses of 50-655 mg, noting that doses above 655 mg may be detrimental.
- Promotes relaxation without sedation by increasing alpha brain wave activity. Modulates GABA, serotonin, and dopamine — particularly effective for stress-related sleep issues.
Ashwagandha (Withania somnifera)
MODERATE-HIGHTherapeutic dose: 300–600 mg/day standardized root extract
- 2021 meta-analysis of 5 RCTs (400 participants) found significant effect on overall sleep (SMD = -0.59). Effects were more pronounced with insomnia diagnosis, dosage ≥600 mg/day, and treatment ≥8 weeks.
- 2024 meta-analysis of 5 RCTs confirmed significant improvements in sleep onset latency, total sleep time, PSQI, and sleep efficiency.
- 2025 analysis of 12 RCTs (600+ participants) reported 72% improvement in sleep quality scores vs placebo and 29% reduction in sleep onset time.
- Primary mechanism is indirect — reduces cortisol and modulates the HPA axis, with additional GABAergic activity. Benefits are strongest in stress-related insomnia.
Moderate Evidence
Glycine
MODERATETherapeutic dose: 3,000 mg (3g) before bedtime
- Three key Japanese studies (Inagawa 2006, Yamadera 2007, Bannai 2012) consistently show 3g glycine before bedtime improves subjective sleep quality and reduces sleep onset latency.
- 2007 PSG study found glycine improved sleep efficiency and shortened latency to slow-wave sleep WITHOUT changing sleep architecture — optimizes natural sleep.
- Mechanism: activates NMDA receptors in the suprachiasmatic nucleus, lowering core body temperature via peripheral vasodilation — the physiological trigger for sleep onset.
- Limitation: all key studies from a single research group (Ajinomoto, a glycine manufacturer). Promising but needs independent replication.
Tart Cherry (Montmorency)
MODERATETherapeutic dose: 480–1,000 mg (or 30 mL concentrate twice daily)
- 2012 RCT (20 volunteers) found tart cherry juice for 7 days significantly increased total sleep time (+34 min) and sleep efficiency (+5-6%). Urinary melatonin metabolite increased ~17%.
- 2023 systematic review and meta-analysis found significant improvements in total sleep time and sleep efficiency on objective measures.
- 2024 RCT found 500 mg tart cherry capsules did NOT improve sleep — suggesting the juice/concentrate form may be necessary.
- Multi-factorial mechanism: natural melatonin, tryptophan, anti-inflammatory anthocyanins, and proanthocyanidins. Anti-inflammatory effect may be more important than melatonin content.
GABA (Gamma-Aminobutyric Acid)
LOW-MODERATETherapeutic dose: 100–300 mg/day
- 2020 systematic review of 14 placebo-controlled trials found mixed results for oral GABA on stress and sleep, with high methodological variability.
- Small RCT of combined GABA/5-HTP found significant reduction in time to fall asleep (32 to 19 min, p = 0.01) and increased sleep duration (5 to 6.8 hrs, p = 0.01).
- Whether supplemental GABA crosses the blood-brain barrier is debated. May act through the enteric nervous system (gut-brain axis) via the vagus nerve.
- PharmaGABA (fermented, natural L-form) may have better efficacy than synthetic GABA.
5-HTP (5-Hydroxytryptophan)
LOW-MODERATETherapeutic dose: 100–300 mg/day
- Direct precursor to serotonin, which converts to melatonin. Crosses the blood-brain barrier readily and is well absorbed orally.
- 12-week RCT (30 older adults, 100 mg/day) showed favorable effects on sleep quality components and increased serum serotonin.
- Combined GABA + 5-HTP showed synergistic effects exceeding either alone in a small human trial.
- Caution: serotonin syndrome risk when combined with SSRIs, MAOIs, or triptans. This is a critical safety consideration.
Apigenin / Chamomile
LOW-MODERATETherapeutic dose: 50 mg isolated apigenin OR 500–1,500 mg chamomile extract
- 2024 meta-analysis of chamomile trials found improved sleep quality (particularly night awakenings), but did NOT improve sleep duration or efficiency.
- Chamomile extract (1,500 mg/day) significantly reduced anxiety in GAD patients in multiple RCTs. Sleep benefits may be secondary to anxiolysis.
- Acts as a benzodiazepine-receptor ligand on GABA-A receptors, producing mild sedative and anxiolytic effects.
- Popularized by Andrew Huberman at 50 mg, but no RCTs exist for isolated apigenin at that dose for sleep. Clinical evidence is for chamomile extract (~1% apigenin).
Saffron (Crocus sativus)
MODERATETherapeutic dose: 28–30 mg/day standardized extract (≥2% safranal, ≥10% crocins)
- 2022 meta-analysis of 8 RCTs (611 participants) found saffron significantly improved PSQI and Insomnia Severity Index scores vs placebo.
- 2023 systematic review of 5 RCTs (379 participants) confirmed beneficial effects on sleep duration and quality, with crocin and safranal inducing hypnotic effects.
- 2025 RCT (165 adults with moderate insomnia): 20–30 mg/day saffron extract for 4 weeks improved sleep quality in a decentralized, double-blind, placebo-controlled trial.
- 2025 RCT in healthy older adults: standardized saffron extract improved subjective and objective sleep quality measures.
- Key limitation: most positive trials use branded extracts (affron®). Mechanism likely involves serotonergic modulation (serotonin → melatonin pathway) and GABAergic activity of crocins.
Weak / No Evidence
Valerian Root
LOWTherapeutic dose: 300–600 mg standardized extract
- 2006 systematic review of 16 RCTs (1,093 patients) found most studies had significant methodological problems. Evidence of publication bias detected.
- 2024 umbrella review concluded evidence on clinical effectiveness is 'very weak' — systematic reviews reached contradictory conclusions.
- Multiple systematic reviews found 9 of 16 studies showed no positive outcomes. Objective sleep measures rarely improved.
- One of the most popular 'sleep herbs' yet evidence is remarkably weak after decades of study. Consumer perception far outpaces clinical support — the 'biotin of sleep.'
Passionflower (Passiflora incarnata)
LOWTherapeutic dose: 250–500 mg extract
- A few small RCTs suggest passionflower may improve subjective sleep quality, primarily through anxiolytic mechanisms.
- One study found passionflower tea for 7 days significantly improved sleep quality on diary measures compared to placebo.
- Often combined with valerian and hops — combination trials show positive results, but cannot attribute effects to passionflower alone.
Vitamin B6 (Pyridoxine)
LOWTherapeutic dose: 1.3–2 mg/day (RDA)
- Required cofactor for converting 5-HTP to serotonin and subsequently to melatonin. Deficiency would impair endogenous melatonin production.
- Some anecdotal reports suggest B6 increases dream vividness, but no robust RCTs for sleep improvement.
- Main value: cofactor supporting melatonin synthesis — relevant when combined with 5-HTP or tryptophan. Similar role to Vitamin C in Skin.
Zinc
LOWTherapeutic dose: 15–30 mg elemental zinc
- 2017 study found zinc supplementation (220 mg zinc sulfate) improved sleep onset latency and sleep efficiency in ICU nurses.
- Limited evidence suggesting zinc may modestly improve sleep quality, potentially through melatonin synthesis support.
L-Tryptophan
LOW-MODERATETherapeutic dose: 1,000–2,000 mg
- L-tryptophan (1-2.4g) has been shown to reduce sleep latency in multiple older studies, but quality was variable.
- Largely superseded by 5-HTP supplementation, which bypasses the rate-limiting tryptophan hydroxylase step.
- The 1989 eosinophilia-myalgia syndrome outbreak was traced to a contaminated batch from one manufacturer, not to tryptophan itself.
Omega-3 Fatty Acids (EPA/DHA)
LOWTherapeutic dose: 1,000–2,000 mg combined EPA/DHA
- Systematic review found omega-3 supplementation associated with improved sleep quality, potentially through anti-inflammatory and serotonin-modulating mechanisms.
- DHA is involved in melatonin synthesis regulation. Supportive role only.
Vitamin D
LOWTherapeutic dose: 1,000–4,000 IU/day
- Low vitamin D status is associated with poor sleep quality in observational studies, but supplementation evidence is mixed.
- May play a supportive role in sleep regulation, but not a primary driver of sleep quality.
Lemon Balm (Melissa officinalis)
LOWTherapeutic dose: 300–600 mg extract
- A small RCT (20 volunteers) of 600 mg lemon balm extract found reduced anxiety and improved sleep quality measures compared to placebo.
- Mechanism involves inhibition of GABA-transaminase, increasing GABA availability. Sleep benefits appear secondary to anxiolytic effects.
- Most commonly studied in combination with valerian — positive combination trials cannot attribute effects to lemon balm alone.
Magnolia Bark (Magnolia officinalis)
LOWTherapeutic dose: 200–500 mg standardized extract
- Contains honokiol and magnolol, which act as positive allosteric modulators of GABA-A receptors — a well-established sedative mechanism.
- Preclinical studies show dose-dependent sedative and anxiolytic effects comparable to benzodiazepines without equivalent side effects.
- Human evidence is very limited. A few small trials suggest improved sleep quality in perimenopausal women, but robust independent RCTs for general sleep are lacking.
CBD (Cannabidiol)
LOWTherapeutic dose: 25–160 mg
- Largest case series (Shannon 2019, 72 adults) found 66.7% improved sleep scores in the first month, but results fluctuated over time and lacked a placebo control.
- One RCT found 160 mg CBD increased total sleep time, but lower doses (40-80 mg) did not — suggesting a high dose threshold if any effect exists.
- Anxiolytic effects at moderate doses (300-600 mg) are better supported than direct sleep effects. Sleep improvement may be secondary to anxiety reduction.
- Deliberately scored low: CBD is the most over-hyped sleep ingredient on the market. Honest scoring here is a key differentiator for BioStacks.
Hops (Humulus lupulus)
LOWTherapeutic dose: 100–500 mg extract
- Contains 2-methyl-3-buten-2-ol, a degradation product of bitter acids that has demonstrated sedative activity in animal models.
- Most human evidence comes from valerian + hops combination trials — a 2010 meta-analysis found the combination modestly effective, but hops' standalone contribution is unclear.
- One small crossover study of hops-enriched non-alcoholic beer found improved sleep quality via actigraphy, but the study design limits generalizability.